Odyssey Therapeutics Appoints Executive Vice President to Strengthen Governance

Jolie Siegel is appointed by Odyssey Therapeutics as the head of legal strategy, risk management and long-term corporate governance.

Odyssey Therapeutics has named Jolie Siegel as the Executive Vice President and General Counsel to further its leadership vision on compliance and governance as the organization pursues its clinical-stage immunology portfolio. Siegel will be in charge of legal matters and risk management and will be a strategic advisor to the executive team and the Board of Directors in her new role.

According to Founder and CEO Gary D. Glick, the appointment is timed at a critical stage of the company as it considers its strategic opportunities and grows its operations. He observed that the background of Siegel in leading BioTech companies in the matter of growth, acquisitions, and regulatory challenges will enable him to develop a robust compliance and governance structure to facilitate long-term value creation.

According to Siegel, the mission of Odyssey to create specific therapies to treat autoimmune and inflammatory diseases seems close to her, referring to her personal experience of the disease's effects. She shared the passion of collaborating with leadership to achieve a sustainable organization that has the capability to produce meaningful patient outcomes through a strong compliance and governance practice.

With the growth of the Odyssey pipeline, Siegel will oversee corporate governance and compliance, security, intellectual property, and contractual and transactional activities. She is a former C4 Therapeutics Chief Legal Officer and Chief Legal Secretary and has been a senior executive at Neon Therapeutics, Intralinks Holdings, and Choate, Hall and Stewart LLP.